Biofidelity is a cancer diagnostics company with mission to enable the early detection of disease and to improve patient outcomes through the implementation of simple yet ultra-high sensitivity diagnostic assays based on our proprietary biochemistry.

Biofidelity is developing a novel molecular diagnostic technology for the detection of smallamounts of circulating tumour DNA in a blood sample.

Biofidelity was founded in 2019 by Barnaby Balmforth and Cameron Frayling. The company is headquartered in Cambridge, United Kingdom.


Biofidelity has developed a novel molecular assay enabling the multiplexed detection of genetic mutations at extremely high sensitivity (<0.1% allele fraction) from tissue or blood samples, without the need for DNA sequencing.


Biofidelity is launching ASPYRE-Lung, a completely new category of molecular diagnostic technology that simplifies and accelerates the detection of genomic biomarkers. 


Biofidelity's ASPYRE-Lung technology has been developed to run on existing PCR machines, the same instrumentation used for COVID-19 testing, making comprehensive genomic biomarker analysis accessible to far more patients around the world.


Biofidelity is backed by BlueYard Capital, Octopus Ventures, SBI Investment Co., Longwall Ventures, Agilent Technologies, and others. The company raised $23M in Series A+ round on Feb 01, 2022. This brings Biofidelity's total funding to $36.7M to date.



  • Year founded: 2018
  • Funding Info: $36.7M over 4 Rounds (Latest Funding Type: Series A+)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Cambridgeshire
  • Country: United Kingdom
Related businesses